Can follow-up be safely de-escalated for patients with low-risk differentiated thyroid carcinoma who achieve an excellent response to initial treatment?
A new multicentre retrospective study found no recurrences among 379 low-risk DTC patients.
🔗 doi.org/10.1530/ETJ-26-0223
![[European Thyroid Journal logo]
Outcomes of patients with low-risk differentiated thyroid cancer with an excellent response to initial therapy
Carlos Garcia-Regal et al.
Figure 2. Cumulative incidence (A) and instantaneous hazard rate (B) of indeterminate or biochemical incomplete response during follow-up according to the ATA 2015 guidelines and the Momesso criteria. The rug marks indicate event times.
Figure 3. Cumulative incidence (A) and instantaneous hazard rate (B) of indeterminate or biochemical incomplete response during follow-up according to the ATA 2025 guidelines the Momesso criteria. The rug marks indicate event times.
Eur Thyroid J (2026) 15 (5): ETJ260223. doi.org/10.1530/ETJ-26-0223](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreihwfk6ymqk4pd22rtf642pixyi5lqtxgr53nuid6gyavuav5fyvwq)
![[European Thyroid Journal logo]
Thyroid disease in pregnancy and the risk of venous thromboembolism: a Danish nationwide cohort study
Ida Marie Nørum Wigh et al.
Figure 2. Bar chart showing the prevalence of venous thromboembolism diagnosed in pregnancy or the following postpartum year in the full nationwide cohort, subcohort 1 and subcohort 2 when stratified by maternal thyroid disease. The illustration includes results of multivariate logistic regression with no thyroid disease as the reference group (Ref.) and reported as adjusted odds ratios (aOR) with 95% confidence interval (CI). See the text for the definition of cohorts and variables included in the adjusted model.
Eur Thyroid J (2026) 15 (5): ETJ260154. doi.org/10.1530/ETJ-26-0154](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreify7mstskosijawi55pjjdadyz2xnkv4nfqzze6sdy2kdq5tn3zma)
![Novel Insights in Advanced Thyroid Carcinoma: From Mechanisms to Treatments Special Collection
[European Thyroid Journal logo]
TERT reactivation in thyroid cancer: mechanisms, clinical implications, and therapeutic opportunities
Linh T T Nguyen, Anthony Glover, Matti Gild, Martyn Bullock
Figure 2. Mechanisms of TERT activation in thyroid cancer. Multiple convergent mechanisms activate TERT transcription in thyroid cancer, leading to both canonical telomerase-dependent and non-canonical telomerase-independent oncogenic effects that collectively drive tumour progression. Eur Thyroid J (2026) 15 (5): ETJ260068.doi.org/10.1530/ETJ-26-0068](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreiaotfacehdkmkwovnrwpdz6s4ry2fc5phowesypmcsw7tnd2mqcuq)
![[European Thyroid Journal logo]
Approaches to thyroid nodules in paediatric cancer predisposition syndromes
Michaela Kuhlen et al.
Figure 1. Framework for evaluation of thyroid nodules in paediatric cancer predisposition syndromes (CPSs). This figure illustrates an integrated, multidisciplinary framework for children and adolescents with CPSs following the detection of a thyroid nodule. Key steps include i) expert high-resolution thyroid ultrasound (US) with systematic cervical lymph node assessment and longitudinal mapping in multinodular disease; ii) early multidisciplinary review after US to confirm risk stratification, define surveillance intervals, and select clinically meaningful targets for biopsy in heterogeneous glands; iii) selective US-guided FNA of nodules chosen on the basis of suspicious sonographic features and syndrome context, acknowledging syndrome-associated pitfalls...Eur Thyroid J (2026) 15 (5): ETJ260100. doi.org/10.1530/ETJ-26-0100.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreigdvobgugetgw55e2vd3npqkfebwndf5gmw5s4su57kxbp6jftxze)
![[European Thyroid Journal logo] Effect of luteal phase support with progesterone on thyroid function: a sub-study of the FET optimizing trial. Diana Grove-Laugesen, Marte Saupstad, Anette Vestergaard Gabrielsen, Eva Ebbehøj, Kristine Løssl, Ulla Breth Knudsen, Anja Pinborg. Figure 2. Plasma progesterone on five specific time points from the day of hCG trigger (day 0) until day 16 in women receiving progesterone luteal phase support or no LPS. LPS, luteal phase support. Progesterone LPS was initiated in the ‘LPS group’ from day 4 after hCG trigger and is indicated with an arrow. Eur Thyroid J (2026) 15 (4): ETJ260099. doi.org/10.1530/ETJ-26-0099](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreif45k5qwvqwgdl3tvxjplf2q3temrrzwq6l42eqkciippg26ngauu)
![[European Thyroid Journal logo] COPZ1 depletion induces cell death through different mechanisms in in vitro murine models of thyroid cancer. Tiziana Di Marco, Debora Vergaro, Mara Mazzoni, Beatrice Mazzoleni, Eleonora Muraro, Sonia Pagliardini, Angela Greco. Figure 1. Susceptibility of murine TC cell lines to COPZ1 silencing. (A) Real-time PCR analysis of murine TC cells for COPZ2 gene expression. Results are presented as relative quantity (RQ) normalized for β-actin housekeeping gene expression. Data represent the mean ± SD of three independent experiments. To compare COPZ2 levels of TC cells with NIH3T3, an unpaired Student’s t-test was applied (**P < 0.01; ***P < 0.001; ****P < 0.0001). (B) Growth assay of murine TC cells 48–96 h after siRNA transfection; the values represent the optical density of crystal violet normalized to control values and are indicated as mean ± SD of three independent experiments;...Eur Thyroid J (2026) 15 (4): ETJ250408. doi.org/10.1530/ETJ-25-0408.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreihx3faqd4u2dcangvu7scda65sb76sboupge2dd47o7xfgcq3ctde)
![[European Thyroid Journal logo]
Optimizing frozen section sampling for thyroid follicular neoplasms through intraoperative ultrasound guidance. Bo Yu, Xin Li, Fang Mei, Jiuping Huang, Shirong Liu, Shi Tan.
Schematic summary of the intraoperative ultrasound-guided optimization of frozen section sampling for thyroid Bethesda IV nodules. Source: created with BioGDP.com. Eur Thyroid J (2026) 15 (4): ETJ260040. doi.org/10.1530/ETJ-26-0040.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreidrnmm6j6bmqmla3cqlseugv6jj3rbvwzblca6vbgbwsodthdmdsu)
![[European Thyroid Journal logo] New Article Type. Clinical Reasoning. Illustrative clinical cases exploring difficult diagnoses or tailored/controversial therapeutic strategies.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreigmyipdkpac3klyxnr7r3xwynpgsisftl5kleavdccpo27e4w4wqu)
![[European Thyroid Journal journal cover]
47th Annual Meeting of the European Thyroid Association (ETA)](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreibmsgevtfx57qmtjpuvpu5fojfgfnl53kauxnaiuj6cjq26axi57q)
![[European Thyroid Journal logo]
[European Thyroid Association logo]
Management of thyroid emergencies: joint consensus statement on management of thyroid storm
Peter Taylor, Onyebuchi Okosieme, Grigoris Effraimidis, Fraser Gibb, Dhruv Parekh, Carla Moran, Peter Kopp, Kristien Boelaert
Figure 1. Overview of treatment strategies for thyroid storm. ATD, antithyroid drug, PTU, propylthiouracil; MMI, methimazole; CBZ, carbimazole; SSKI, saturated solution of potassium iodide; C-XRAY, chest X-ray; ECG, electrocardiogram, HDU, high-dependency unit.
Eur Thyroid J (2026) 15 (4): ETJ260043. doi.org/10.1530/ETJ-26-0043](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:yjgozih3olalatjxpxof4j7p/bafkreihsmdz7ad2vtikfqof7sir7tmkdddvmiu32htudu44grdn4dyczem)
